After 5-month hiatus, bluebird bio’s Zynteglo bounces back in Europe with all-clear from safety groupnews2021-07-09T15:21:37+00:00July 9th, 2021|Fierce Pharma|
England’s drug price watchdog rejects Orchard’s groundbreaking gene therapy after first round of talksnews2021-07-09T15:07:23+00:00July 9th, 2021|Fierce Pharma|
What heart safety concern? Doctors like Incyte’s eczema cream despite potential JAK warning: analystnews2021-07-09T14:30:29+00:00July 9th, 2021|Fierce Pharma|
Philip Morris strikes $1.45B deal for Vectura, sending another would-be buyer back to the drawing boardnews2021-07-09T13:38:29+00:00July 9th, 2021|Fierce Pharma|
Philip Morris strikes $1.45B deal for Vectura, sending another would-be buyer back to the drawing boardnews2021-07-09T13:38:29+00:00July 9th, 2021|Fierce Pharma|
Moving the vaccination needle: Study examines behavioral tactics that work—and don’tnews2021-07-09T13:17:51+00:00July 9th, 2021|Fierce Pharma|
Fierce Pharma Asia—Ex-Genentech staffers’ IP theft; Lundbeck’s Alzheimer’s deal; China’s oncology R&D rulenews2021-07-09T11:36:21+00:00July 9th, 2021|Fierce Pharma|
Johnson & Johnson’s Stelara posts positive 3-year data in ulcerative colitis as competition heats upnews2021-07-09T10:52:55+00:00July 9th, 2021|Fierce Pharma|
Johnson & Johnson’s Stelara posts positive 3-year data in ulcerative colitis as competition heats upnews2021-07-09T10:52:55+00:00July 9th, 2021|Fierce Pharma|
Pfizer plots course for COVID-19 booster, but the CDC isn’t sure ‘whether or when’ follow-up shots will be needednews2021-07-09T00:56:33+00:00July 9th, 2021|Fierce Pharma|
